Figure 2

miR-148a modified the cisplatin sensitivity of A549/DDP and SPC-A1/DDP cells. (A) After A549/DDP and SPC-A1/DDP cells transfected by miR-148b mimic or NC for 24 h, the cells were incubated with various doses of cisplatin (10, 20, 40, 80, 160, 320 μmol/L) for 48 h , and then cells viability was assessed by MTT assay. In A549/DDP cell, IC50miR-148b mimic is 55.36 μmol/L, IC50NC is 173.27 μmol/L; in SPC-A1/DDP cell, IC50miR-148b mimic is 44.25 μmol/L, IC50NC is 156.32 μmol/L. (B) After A549 and SPC-A1 cells transfected by miR-148b inhibitor or NC for 24 h, the cells were incubated with various doses of cisplatin (2, 4, 8, 16, 32 μmol/L) for 48 h, and then cells viability was assessed by MTT assay. In A549 cell, IC50miR-148b inhibitor is 45.06 μmol/L, IC50NC is 9.21 μmol/L; in SPC-A1 cell, IC50miR-148b inhibitor is 44.62 μmol/L, IC50NC is 6.97 μmol/L. (C) After A549/DDP cells treated by NC or miR-148b mimic for 24 h, and incubated with 10 μmol/L cisplatin for 48 h, cells apoptosis was evaluated using flow cytometry. Data were represented as mean ± SD. *P <0.05 compared with cells treated with the same concentration of ciaplatin accordingly.